Recently, Tian Tan Bio announced that its subsidiary, China National Pharmaceutical Group Wuhan Biological Products Co., Ltd., has developed "Intravenous COVID-19 Human Immunoglobulin (pH4)" which is currently in the Phase II clinical trial stage. After a comprehensive evaluation, the company has decided to terminate the Phase II clinical trial and subsequent research and development of the drug.

According to the announcement, the total R&D investment for the intravenous COVID-19 human immunoglobulin (pH4) amounts to 121 million yuan, which includes research and development expenses and equipment purchase costs. Among these, the cumulative R&D expenses totaled 117 million yuan, already accounted for in previous fiscal periods, while -0.04 thousand yuan will be accounted for in the 2024 fiscal year.

Data shows that Tian Tan Bio's main business is the research and production of blood products using healthy human plasma or plasma from specifically immunized healthy individuals as raw materials, employing genetic recombination technology, and engaging in blood product operations.

In the first three quarters of 2024, Tian Tan Bio achieved operating revenue of 4.073 billion yuan, a year-on-year increase of 1.28%; the net profit attributable to shareholders was 1.052 billion yuan, up 18.52%; and the net cash flow generated from operating activities was 1.299 billion yuan, a year-on-year decrease of 44.52%.

https://finance.eastmoney.com/a/202412303282551013.html